mRNA |
lapatinib |
CCLE |
pan-cancer |
AAC |
0.12 |
0.01 |
mRNA |
ML311 |
CTRPv2 |
pan-cancer |
AAC |
-0.081 |
0.01 |
mRNA |
S-Trityl-L-cysteine |
FIMM |
pan-cancer |
AAC |
-0.42 |
0.01 |
mRNA |
selumetinib:PLX-4032 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.088 |
0.01 |
mRNA |
procarbazine |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.02 |
mRNA |
MS-275 |
gCSI |
pan-cancer |
AAC |
-0.13 |
0.02 |
mRNA |
Vandetanib |
FIMM |
pan-cancer |
AAC |
-0.41 |
0.02 |
mRNA |
R428 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.02 |
mRNA |
docetaxel:tanespimycin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.081 |
0.02 |
mRNA |
triazolothiadiazine |
CTRPv2 |
pan-cancer |
AAC |
-0.073 |
0.02 |